Initiator Pharma A/S is a Danish registered company, and is reporting its financial situation in Danish kroner (DKK). Initiator Pharma A/S was registered on May 2, 2016.
|Third Quarter (2018-07-01 – 2018-09-30)|
|First Nine Months of the Year (2018-01-01 – 2018-09-30)|
Group earnings per share: period result divided by a number of 17 367 884 stocks (on 2018-09-30). Solidity: equity divided by assets.
Business highlights in Q3 2018
Significant events after this reporting period
Comments from the CEO
”With the initiation of the Phase 1 trial of IPED2015 during Q3:18 Initiator Pharma has made the transformation into a clinical stage company. We have big expectations that IPED2015 will become a first in class oral treatment of Erectile Dysfunction for the large number of patients that do not respond to drugs in the PDE5i class. Contingent on a successful completion on the Phase 1 trial we remain optimistic that we will be able to complete the clinical phase IIa Proof of Concept in the first half of 2019.
While maintaining full focus on the development program for IPED2015 we are also looking forward to leveraging the expertise within Initiator Pharma by expanding our pipeline with attractive assets that can provide value to the company and shareholders in addition to helping patients with unmeet needs”
For more information, please contact
Claus Olesen, CEO, Initiator Pharma, Mobile: +45-61 26 00 35, E-mail: firstname.lastname@example.org
Torgeir Vaage, CFO, Initiator Pharma, Mobile: +47-924 05 235, E-mail: email@example.com
About Initiator Pharma
Initiator Pharma A/S is a Danish biotechnology company focusing on the development of innovative drugs, targeting key unmet medical needs within the central and peripheral nervous system. Our research is focusing on monoamine reuptake inhibitors, molecules that are affecting the synaptic concentrations of neurotransmitters such as dopamine, serotonin and noradrenaline. Our lead drug candidate, IPED2015 is targeting the medical condition Erectile Dysfunction (ED), and specifically patients with ED that are non-responsive to drugs within the PDE5i class, including the approved drugs ViagraÓ, CialisÓand LevitraÓ.
Initiator Pharma is based in Aarhus, Denmark. Initiator Pharma is listed on Spotlight Stockmarket and has about 3.600 shareholders. Read more at www.initiatorpharma.com.